SymBio Pharmaceuticals Ltd
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
TOKYO, 2016-06-13 07:32 CEST (GLOBE NEWSWIRE) --
SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for patient-controlled short-term management of acute postoperative pain during hospitalization, was initiated in Japan, (“the Product”).
SymBio obtained the exclusive development and commercialization rights to the Product in Japan from The Medicines Company (Headquarters: New Jersey, U.S.) in October, 2015. The Product, launched in the U.S., was approved by the U.S. Food and Drug Administration (FDA) in April, 2015 and also approved by the European Medicines Agency (EMA) in November, 2015.
SymBio will actively proceed with this Phase 3 clinical trial, aiming for the Product’s manufacturing and marketing approval in Japan in 2019.
This event will not impact the Company’s current financial forecast.
Tel: +81 (0)3 5472 1125
About The Medicines Company
The Medicines Company was founded in 1996 in the U.S. and is led by a multidisciplinary team with significant experience in pharmaceutical product development and commercialization.
The Company’s purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on the leading acute and intensive care hospitals worldwide. The Company’s vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care and serious infectious disease care. For more information, please visithttp://www.themedicinescompany.com/.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, USA, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
XBiotech Inc.12.12.2018 14:32 | Pressemeddelelse
XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease
Cisco12.12.2018 14:01 | Pressemeddelelse
Cisco and UBS to host ESG Conference Call/Webcast for the Financial Community on 12/17/18
DoubleVerify11.12.2018 18:05 | Pressemeddelelse
DoubleVerify and InMobi Unite to Combat Mobile App Fraud
Claroty11.12.2018 15:03 | Pressemeddelelse
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform
Farmako GmbH11.12.2018 10:01 | Pressemeddelelse
Farmako: Cannabis distributor to become gateway to Europe
Graduate Management Admission Council10.12.2018 16:28 | Pressemeddelelse
The Graduate Management Admission Council Selects Three New Business Schools for Membership
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum